News stories about Shire PLC (NASDAQ:SHPG) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Shire PLC earned a news impact score of 0.14 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.1891051027788 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the headlines that may have impacted Accern’s scoring:
- Shire PLC (SHPG) Sees Significant Increase in Short Interest (americanbankingnews.com)
- Shire PLC (SHPG) Receives Buy Rating from Cantor Fitzgerald (americanbankingnews.com)
- Shire Debuts MYDAYIS® and New Research at the 30th Annual Psych Congress (globenewswire.com)
- Shire to present research on recently approved ADHD med Mydayis at upcoming Psych Congress; shares up 2% premarket (seekingalpha.com)
- What’s Cooperman’s View on Shire? (finance.yahoo.com)
Several research analysts have recently weighed in on the stock. BidaskClub downgraded shares of Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Friday, June 16th. Barclays PLC downgraded shares of Shire PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 11th. Sanford C. Bernstein downgraded shares of Shire PLC from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $209.22 to $161.09 in a research note on Thursday, May 25th. Evercore ISI assumed coverage on shares of Shire PLC in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $196.00 target price for the company. Finally, Cantor Fitzgerald set a $222.00 target price on shares of Shire PLC and gave the company a “buy” rating in a research note on Saturday, July 1st. One analyst has rated the stock with a sell rating, ten have issued a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $220.08.
Shire PLC (SHPG) traded up 0.40% during trading on Friday, reaching $158.46. 3,043,517 shares of the company’s stock traded hands. The firm’s 50 day moving average is $153.42 and its 200-day moving average is $168.82. Shire PLC has a 12 month low of $139.36 and a 12 month high of $209.22. The company has a market capitalization of $47.98 billion, a price-to-earnings ratio of 70.90 and a beta of 1.61.
Shire PLC (NASDAQ:SHPG) last issued its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. Analysts expect that Shire PLC will post $14.93 EPS for the current fiscal year.
The company also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 8th will be paid a $0.1527 dividend. The ex-dividend date is Thursday, September 7th. This represents a yield of 0.21%. Shire PLC’s dividend payout ratio (DPR) is presently 41.07%.
TRADEMARK VIOLATION WARNING: This piece of content was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/09/17/shire-plc-shpg-getting-somewhat-favorable-news-coverage-analysis-shows.html.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.